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Summary Flow cytometric studies of T-lymphocytes in breast cancer patients show that the number of cells
bearing ferritin on their surface is significantly greater than normal. The number of ferritin-bearing T-cells
does not appear to be related to the clinical stage of the disease nor to the serum ferritin concentration,
though this is higher in cancer patients than in normal women. There is no difference in the number of T-cells
positive for interleukin 2 or transferrin receptors nor in the absolute number of T-cells, T-helper cells and
B-cells between normal women and those with breast cancer or benign breast disease. However, there is a
significant increase in the level of HLA DR-positive T-cells and T-suppressor cells in breast cancer patients.
While the significance of ferritin-bearing T-cells is not known an increase in their number appears to be
associated with cancer.
Ferritin is generally regarded as an iron storage protein, the
small amount of ferritin normally present in serum reflecting
the level of storage iron in the body (Jacobs & Worwood,
1975; Worwood, 1982). Elevated levels of serum ferritin are
found in iron overload states but have also been described in
many malignant diseases (Jacobs, 1984). Some authors have
linked the high serum ferritin concentrations in cancer
patients to a variety of immunosuppressive effects involved
in cellular immunity (Levy & Kaplan, 1974; Matzner et al.,
1979; Hancock et al., 1979). There is evidence for a sub-
population of lymphocytes from the peripheral blood of
patients with breast cancer and Hodgkin's disease which
bears surface membrane ferritin (Moroz et al., 1977a,b), and
it has been suggested that this may be responsible for a
suppressive effect on T-cell function.
It is known that the raised concentration of ferritin found
in serum from patients with leukaemia (Worwood et al.,
1974; Parry et al., 1975) and Hodgkin's disease (Sarcione et
al., 1977) is associated with an increased concentration of
ferritin in circulating leukocytes. Cragg et al. (1984) showed
that the majority of monocytes and B lymphocytes in normal
peripheral blood have a significant amount of surface
ferritin, whereas only a small fraction of T-cells had ferritin
on their surface. The presence of surface ferritin on only a
minor fraction of T-cells is unlikely to be due to a difference
in endogenous production as T-cell ferritin synthesis is
greater than that of B cells (Dorner et al., 1980). The
presence of B-cell surface ferritin is compatible with the
suggestion that the protein may play a part in determining
lymphocyte movement in the body (de Sousa et al., 1978).
A number of studies show a good relationship between the
development of cancer and increased lymphocyte-bound
ferritin (Moroz et al., 1984; Bluestein et al., 1984; Jacobs et
al., 1984) and there is a potential diagnostic and prognostic
value of enumerating ferritin-bearing lymphocytes in breast
cancer patients. However, it is not clear whether ferritin
present on the surface of lymphocytes in cancer patients is a
specific binding of ferritin to the lymphocyte surface
associated with a high circulating ferritin concentration, or if
it has a more specific significance. Following mitogen
stimulation there is a marked increase in the number of
T-cells bearing ferritin on their surface membrane and this
coincides with an increase in other proliferative markers
(Pattanapanyasat et al., 1987).
The aim of the study was to use flow cytometry to
measure ferritin and other T-cell surface markers to
investigate the interrelationship with the iron status,
lymphocyte activation and clinical status of patients with
breast cancer.
Materials and methods
Subjects
Patients referred to the breast clinic at the University
Hospital of Wales, Cardiff, were eligible for this study. They
were between 34 and 87 years old, approximately one half
were younger than 55 years. The clinical and histopatho-
logical diagnosis including involvement of axillary lymph
nodes and staging of the disease was filed in the Department
of Surgery and not decoded until all the laboratory studies
were complete.
Of the 70 untreated breast disease patients, 50 had breast
cancer and were staged according to the TNM classification.
The other 20 had benign disease and were divided into
inflammatory and non-inflammatory disease. Twenty healthy
women matched by age were used as a control group. Five
patients with idiopathic haemochromatosis, 2 thalassaemic
patients with iron overload and 9 patients with iron
deficiency anaemia served as pathological controls. All
subjects gave fully informed consent.
Methods
Twenty millilitres of peripheral blood containing 20 units
ml- 1 heparin was collected for lymphocyte studies in
addition to 10ml blood for routine blood counts or serum
ferritin estimation.
Preparation of mononuclear cells Heparinized blood was
layered over Percoll (Pharmacia), density 1.077 (Ali et al.,
1982), and centrifuged at 400g for 30min. The band of
mononuclear cells was removed, washed twice by adding
20ml of RPMI 1640 medium (Flow Laboratories), mixed
and centrifuged at 500g for 10min. The washed cells were
resuspended in 2ml with medium and counted with a
Coulter counter model ZF.
Antibodies and staining reagents Anti-interleukin-2 receptor
(Anti-Tac (CD 25) was a gift from Dr Waldman, NIH,
Bethesda, USA). Anti-Leu 1 PE (CD 5), a monoclonal pan
T-cell antibody conjugated with phycoerythrin; anti-
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transferrin receptor conjugated with fluorescein isothio-
cyanate (FITC) and anti-HLA DR conjugated with FITC
were obtained from Becton Dickinson. OKT4 (CD 4), OKT8
(CD 8) and BAI (CD 24) were used in this study to
investigate the proportion of T-helper cells, T-suppressor
cells and B-cells. These 3 antibodies are all purified
unconjugated mouse monoclonal antibodies. OKT4 and
OKT8 were obtained from Ortho Diagnostic System, BAl
was obtained from Coulter Immunology. Antibodies to
purified human spleen and heart ferritin were raised in sheep
and rabbit by Dr M. Worwood. Antibody to heart ferritin
was absorbed with human spleen ferritin (Jones & Worwood,
1978). Both the anti-spleen and anti-heart ferritin used were
immunoglobulin fractions obtained from sodium sulphate
precipitation of antiserum (Conradie & Mbhele, 1980).
Streptavidin-FITC (Amersham), biotinyl-N-hydroxysuccin-
imide (BNHS), N,N-dimethylformamide (DMF), sheep and
rabbit immunoglobulin (Sigma) were also used.
Biotinylation offerritin antibody (Guesdon et al., 1979) Five
mg of either spleen or heart ferritin antibody was dissolved
in 1 ml of sodium bicarbonate pH 8.0, incubated with 125pl
BNHS (8mg BNHS in 1 ml DMF) for 2h at room
temperature and dialysed overnight at 40C against several
changes of PBS. After centrifugation at 500g for 10min the
supernatant was added to an equal volume of glycerol and
kept at -20°C until required.
Determination of ferritin-bearing T-lymphocytes This was
performed by a dual immunofluorescence technique using
the biotin-streptavidin system (Pattanapanyasat et al., 1987).
Determination of other surface antigens T-lymphocytes
reactive with anti-transferrin receptor and anti-HLA DR
were also detected by a dual fluorescence technique. One
million cells were incubated with anti-Leu 1 PE as described
above. After 2 washes, they were further incubated either
with 5 p1 anti-transferrin receptor-FITC or 5 p1 anti-HLA
DR-FITC. After 30min incubation on ice in the dark, cells
were washed twice and resuspended in PBS for FACS
analysis.
Tac positive, T-helper cells, T-suppressor cells and B-cells
were determined by indirect immunofluorescence by
incubating 1 x 106 cells with 5pl of either anti-Tac (1:5,000
final dilution) OKT4, OKT8 or BAl on ice for 30min. The
cells were washed and 5yl fluorescein-labelled rabbit anti-
mouse immunoglobulin antibody (DAKO) was added. After
30min incubation, the cell suspensions were washed and
analysed as above. All antibodies were used at
concentrations which yielded maximal fluorescence. Controls
were processed in the same way except omitting the first
antibody.
Fluorescence analysis For each stained sample, 5,000 cells
were analysed for fluorescence intensity after light scatter
gating to select the lymphocyte population. The fluorescence
distributions for both the control and test cells without
antibody and the cell population with antibody were
analysed. The percentage of positive cells with the various
antibodies was calculated by subtracting the scaled control
from the test distribution. The appropriate scale was
determined from a least squares fit summed over the
channels up to the first maximum of the control distribution.
Serum ferritin concentration Serum ferritin concentration
was measured by immunoradiometric assay (Worwood,
1980).
Statistical analysis The statistical significance of difference
between results was determined either by Student t test for
mean significance of sample groups containing more than 30
subjects or the Mann-Whitney U-test on groups containing
fewer than 30 observations.
Results
Serumferritin concentration
The mean serum ferritin concentration in 50 cancer patients
was significantly higher (P<0.05) than in normal subjects or
those with benign breast disease (Figure 1), despite a wide
variation in the results and the presence of a well defined
group with pathologically low serum ferritin concentration,
presumably due to coexistent iron deficiency. However, there
was no statistically significant difference between cancer
patients with different disease staging.
Expression of T-lymphocyte surfaceferritin
The number of ferritin-bearing T-cells in different groups of
subjects are shown in Figures 2 and 3. The mean percentage
of spleen ferritin-bearing T-cells in 50 patients with breast
cancer was significantly higher (P<0.001) than in normal
controls. However, there was no significant difference
between the levels in normal controls and patients with
either benign breast disease or iron deficiency anaemia. It is
interesting that two homozygous beta-thalassaemic patients,
whose serum ferritin concentrations were > 1700pg1-1
showed a low percentage of ferritin-bearing T-cells. Patients
with benign inflammatory disease have a higher number of
ferritin-positive cells than those with non-inflammatory
disease.
The mean percentage of heart ferritin-bearing T-cells in 30
cancer patients was higher (P<0.001) than the mean from 8
normal subjects (Figure 3). However, there was no statistical
difference between the patients with cancer and benign
disease. The bimodal distribution of serum ferritin levels in
cancer patients is not reflected by a similar bimodality in the
number of ferritin-positive lymphocytes.
Percentage offerritin-bearing T-cells, disease stages and
serumferritin levels
In order to assess the value of ferritin-positive T-cells as a
diagnostic tool, a normal upper cut-off of 7.0% for spleen
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Figure 1 Serum ferritin concentration in different groups of
subjects. N =Normal; B =Benign breast disease; CA =Breast
cancer, stages I, II, III and IV; ,BT=,B-Thalassaemia; IDA=Iron
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ferritin and 7.8% for heart ferritin-bearing T-cells was used,
these being the 95% confidence limits for the normal group.
Only 2 out of 20 normal subjects (10%) had higher levels of
spleen ferritin-bearing T-cells. In contrast, 78% of cancer
patients showed elevated values. Of these 39 patients, 13 of
the 17 (76%) with stage I, all 11 with stage II, 11 of the 18
(63%) with stage III disease and all 4 patients with stage IV
** advanced disease had elevated values above the cut-off level
(Figure 2). However, there was no relationship between the
. * percentage positive cells and the clinical stage of malignancy.
Although 7 out of 20 (35%) patients with benign breast
disease did show increased levels, 6 of these were among the
- 7 patients with inflammatory breast disease, whereas only 1
out of 13 patients with non-inflammatory disease showed
this phenomenon. None of the normal subjects had more
than 7.8% heart ferritin-bearing T-cells, whereas 3 out of 8
* .. ** patients with benign disease (38%) and 20 out of 30 cancer
.*: patients (67%) showed elevated values. There was no
relationship between the percentage of heart ferritin-bearing
T-cells and clinical stage.
IS " There is no overall correlation between the percentage
B INF NIF ferritin-positive T-cells and serum ferritin concentration. The
presence of nodal involvement in breast cancer patients was
not related to the percentage of ferritin-positive T-cells
(Table I).
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Other T-cell surface antigens
Measurement of Tac and transferrin receptors on T-cells in
normal subjects and patients with breast disease showed no
significant difference in their levels, whereas in cancer
patients 13.4 +6.0% of T-cells were HLA-DR positive
compared to 5.4+7.5% in normal subjects (P<0.01) and
11.5 + 5.0% in patients with benign breast disease (NS) (data
not shown). There was no significant difference in total T-
cells, T-helper or B-cells between normal and breast disease
patients. However, T-suppressor cells in cancer patients
(23.6+5.9%) were significantly increased (P <0.001)
compared to either normal subjects (18.9 +9.0%) or patients
with benign breast disease (17.5 +7.3%) (data not shown).
Discussion
In this study serum ferritin concentrations in normal subjects
and patients with iron deficiency or overload are similar to
those found previously (Jacobs et al., 1972; Worwood, 1982).
It also confirms other earlier reports (Marcus & Zinberg,
1975; Jacobs et al., 1976) of high circulating ferritin levels in
patients with breast cancer. There are many possible causes
of raised serum ferritin levels in malignancy, including
increased iron stores, release of ferritin from inflamed tissues
and production of ferritin by proliferating tumour cells
(Jacobs & Worwood, 1975). Although it is tempting to
consider it as a tumour associated protein, the reason is still
far from clear (Jacobs, 1984).
Measurement of T-lymphocyte surface ferritin shows that
the mean percentage of ferritin-positive T-cells in breast
cancer patients is significantly higher than in normal subjects
and in patients with benign breast disease. Seventy to eighty
percent of cancer patients have an increased percentage of
ferritin-bearing T-cells, compared to less than 10% in the
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Figure 3 Distribution of the percentage of heart ferritin-positive
T-cells in different subjects. N =Normal; B = Benign breast
disease; CA = Breast cancer, stages I, II, III and IV; ------
Normal upper limit.
Table I Distribution of the percentage of
spleen ferritin-positive T-cells and node status
in breast cancer patients
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control group. These results are consistent with other
investigations in patients with mammary carcinoma (Moroz
et al., 1984; Bluestein et al., 1984) and other malignant
diseases (Bluestein et al., 1984; Steinhoff et al., 1984;
Papenhausen et al., 1984).
Of greater importance is the correlation between ferritin-
bearing lymphocytes and the clinical stage of the disease;
unfortunately there is some disagreement in this area. Moroz
et al. (1984) found that the level of ferritin-positive cells in
breast cancer patients was elevated in stages I, II and IV, but
low in stage III. In our study, although there is a significant
increase in spleen ferritin-bearing T-cells in all stages of
breast cancer, this does not appear to be related to disease
stage (Figure 2). However, there is an increased level in only
61% of stage III patients compared to stage I (76%), stage
II (100%) and stage IV (100%). Moroz et al. (1984)
hypothesised that this rather surprising finding in stage III
patients may be due to deranged traffic of ferritin-bound
lymphocytes, which accumulate at an extravascular site to be
replaced in the blood by other lymphocytes, as suggested by
the studies of De Sousa et al. (1978). Jacobs et al. (1984)
found an elevated level of spleen ferritin-bearing lymphocytes
in patients with Hodgkin's disease, but no relationship to
disease stage. A similar result has also been reported in
patients with head and neck cancer (Papenhausen et al.,
1984).
Spleen ferritin-positive T-cells show no significant
difference between the normal controls, patients with benign
breast lesion, patients with iron deficiency anaemia and
patients with idiopathic haemochromatosis. Although 8 out
of 20 patients with benign breast disorders show elevated
levels of T-cells bearing spleen ferritin, 6 of these are of an
inflammatory type and the phenomenon may be a result of
T-cell activation (Pattanapanyasat et al., 1987). This could
also explain the increased number of HLA-DR positive cells
in breast cancer patients.
This study shows that there are zero or low Tac-positive
and transferrin receptor-positive T-cells in breast cancer
patients. It is known that T-cell proliferation is dependent on
the presence of Tac antigen (Uchiyama et al., 1981),
transferrin receptor (Larrick & Cresswell, 1979), and HLA-
DR antigen (Ko et al., 1979) and that resting T-cells possess
few of these molecules. It is unusual to see an increase in the
level of HLA-DR positive T-cells unrelated to other
proliferative markers, but it may simply be that the degree of
HLA-DR positivity found here is a response to mild
stimulation and is certainly not comparable to that seen in
mitogen stimulated T-cells (Ko et al., 1979; Pattanapanyasat
et al. 1987) where levels are 5-6 times higher than in normal
T-cells.
Similarly, heart ferritin-bearing T-cells show no
relationship with the clinical disease stage. Measurements of
T-cells bearing either spleen or heart ferritin do not appear
to discrminate between the clinical stage of breast cancer.
However, it is able to differentiate, to some extent, between
patients with benign breast disease and patients with breast
carcinoma, or between normal and cancer patients and it
might help in identifying some patients with inflammatory or
premalignant breast lesions.
It has been suggested that ferritin may play a crucial role
in suppressing normal T-cell function (Matzner et al., 1979;
Hancock et al., 1979). Our results show no correlation
between T-cells bearing ferritin and serum ferritin concen-
tration. This suggests that the increased number of T-cells
bearing ferritin is not secondary to high circulating levels.
Moreover, a low percentage of T-cells bearing ferritin has
been demonstrated in both patients with homozygous beta-
thalassaemia and hyperferritinaemia. Moroz et al. (1977b)
found 4 patients with thalassaemia to be devoid of ferritin-
bearing lymphocytes. Recently, Steinhoff et al. (1984) studied
lymphocyte surface ferritin in patients known to have high
levels of serum ferritin, such as haemochromatotic patients,
patients with rheumatoid arthritis and patients with bacterial
infection. None of them had elevated levels of lymphocyte-
bearing ferritin.
At present, the precise subset of lymphocytes in breast
cancer patients to which the ferritin-bearing lymphocytes
belong is unknown. Cragg et al. (1984) showed that a minor
fraction of both T-helper and T-suppressor cells have surface
ferritin. In addition, our results show that the level of
peripheral blood T-suppressor cells in patients with breast
cancer is higher than that of normal subjects, though
whether there is any connection with an increase in ferritin-
bearing T-cells is not clear.
Although the functional significance of this phenomenon
is unknown, it may prove to be another useful indicator of
the presence of malignancy along with other tumour
markers.
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